Page 151 - Genentech News Today

Investigational treatment found to be highly effective in blocking gluten-specific T cells in celiac disease.

Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told apart by the activity of key cells and signaling pathways, a new study shows.

Dailyrepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrepublic.com Daily Mail and Mail on Sunday newspapers.

BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including

/PRNewswire/ -- The "Global Microbiome Partnering Terms and Agreements 2010 to 2023" report has been added to ResearchAndMarkets.coms offering. This report...

/PRNewswire/ -- Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told...

The Supreme Court last week unanimously affirmed a Federal Circuit decision finding that patent claims for Amgen's Repatha® that cover "the entire genus"...

By Michael Erman (Reuters) -Swiss drugmaker Roche Holding AG plans to sell its 800-employee drug manufacturing plant in Vacaville, California, or it will ...

Potentially registrational trial with Nykode’s lead candidate VB10.16 and Roche’s atezolizumab in the U.S. is expected to be initiated 4Q 2023OSLO, Norway, June 01, 2023 -- Nykode... | June 1, 2023

Subcutaneous delivery of fixed-dose adjuvant pertuzumab plus trastuzumab proved to have favorable tolerability, with a safety profile consistent with that seen with intravenous delivery of the regimen in patients with HER2-positive breast cancer.